Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agomelatine combined with cognitive behavioral therapy for chronic insomnia with mild depression
ChiCTR1800018822Phase 4Recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of agomelatine, zolpidem and Placebo-COD Research Private Ltd in chronic insomnia and major depressive disorder (MDD) (3 arms), sponsored by Shanghai Changzheng Hospital. Primary endpoints: Polysomnography, Clinical rating scales and 11 more. Started Nov 2018; status: recruiting.
02
Drugs
agomelatinezolpidemPlacebo-COD Research Private Ltd
03
Conditions
chronic insomniamajor depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR1800018822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018822.